Valuation: BioNTech SE

Market Cap 20.47B 23.34B 19.01B 17.45B 32.87B 2,256B 33.38B 226B 88.53B 1,105B 87.65B 85.77B 3,807B P/E 2026 *
-18.4x
P/E 2027 * -17.7x
Enterprise Value 9.61B 10.96B 8.93B 8.2B 15.44B 1,059B 15.68B 106B 41.58B 519B 41.16B 40.28B 1,788B EV / Sales 2026 *
4.43x
EV / Sales 2027 * 5.01x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.54%
1 week+1.58%
Current month-1.31%
1 month+1.03%
3 months-17.72%
6 months-22.18%
Current year-3.54%
1 week 90.6
Extreme 90.595
93.9
1 month 88.35
Extreme 88.35
98.81
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 60 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 55 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Date Insider Type Main position Quantity % Market Cap.
5/12/26 Free

Executive/Senior Manager

22,655 0.0094%
5/12/26 Free

Chief Operating Officer

22,655 0.0094%
5/12/26 Free

Chief Financial Officer

33,982 0.0141%
Change 5-day change 1-year change 3-year change Capi.($)
-0.54%+1.58%-15.68%-15.43% 23.35B
-0.43%-1.26%+52.13%+85.69% 55.57B
-0.24%-0.37%+57.02%+54.21% 54.26B
-1.82%-3.15%+3.76%+405.88% 23.54B
+0.05%+1.68%+38.71%-4.57% 20.32B
+3.16%+2.74%+37.33%-31.36% 17.36B
+1.08%+3.77%+36.92%+593.96% 15.59B
+0.43%-1.67%+166.53%+299.61% 14.96B
-2.03%-1.42%+24.22%+179.23% 14.11B
-1.67%+0.15%+62.46%+149.20% 12.61B
Average -0.20%-0.02%+46.34%+171.64% 25.17B
Weighted average by Cap. -0.25%-0.13%+45.07%+136.75%

Financials

2026 *2027 *
Net sales 2.17B 2.47B 2.01B 1.85B 3.48B 239B 3.54B 23.98B 9.38B 117B 9.29B 9.09B 403B 2.23B 2.54B 2.07B 1.9B 3.58B 246B 3.64B 24.67B 9.65B 120B 9.55B 9.35B 415B
Net income -1.04B -1.19B -968M -889M -1.67B -115B -1.7B -11.53B -4.51B -56.28B -4.46B -4.37B -194B -1.16B -1.33B -1.08B -993M -1.87B -128B -1.9B -12.88B -5.04B -62.89B -4.99B -4.88B -217B
Net Debt -10.85B -12.38B -10.08B -9.26B -17.43B -1,196B -17.71B -120B -46.96B -586B -46.49B -45.49B -2,019B -9.29B -10.59B -8.63B -7.92B -14.91B -1,023B -15.15B -103B -40.17B -501B -39.77B -38.92B -1,727B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-07-22 US$91.83 -0.54% 508,116
26-07-21 US$92.33 +0.18% 696,991
26-07-20 US$92.16 +0.74% 687,738
26-07-17 US$91.48 -0.09% 1,131,172
26-07-16 US$91.56 -0.47% 670,293
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
80.93EUR
Average target price
106.79EUR
Spread / Average Target
+31.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock